| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695627P | 2018-07-09 | 2018-07-09 | |
| US201862695623P | 2018-07-09 | 2018-07-09 | |
| US201962863710P | 2019-06-19 | 2019-06-19 | |
| US201962864367P | 2019-06-20 | 2019-06-20 | |
| US201962866420P | 2019-06-25 | 2019-06-25 | |
| PCT/US2019/041085WO2020014285A2 (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
| Publication Number | Publication Date |
|---|---|
| SG11202100208VAtrue SG11202100208VA (en) | 2021-02-25 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100208VASG11202100208VA (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
| Country | Link |
|---|---|
| US (2) | US11535669B2 (en) |
| EP (1) | EP3820496A4 (en) |
| JP (2) | JP7617839B2 (en) |
| KR (1) | KR20210042909A (en) |
| CN (1) | CN112672753B (en) |
| AU (1) | AU2019301070B2 (en) |
| CA (1) | CA3105750A1 (en) |
| IL (1) | IL279965A (en) |
| SG (1) | SG11202100208VA (en) |
| WO (1) | WO2020014285A2 (en) |
| ZA (2) | ZA202100390B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102742741B1 (en)* | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | Polypeptide composition comprising a spacer |
| CN110734498A (en)* | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | fusion protein for relieving immunosuppression and application thereof |
| EP4048704A4 (en)* | 2019-10-21 | 2023-11-22 | Nanjing Leads Biolabs Co., Ltd. | RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß |
| EP4051279A1 (en) | 2019-11-01 | 2022-09-07 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| KR20220097443A (en) | 2019-11-05 | 2022-07-07 | 메르크 파텐트 게엠베하 | Combination inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer |
| CN115397973A (en)* | 2020-01-30 | 2022-11-25 | 免疫生物公司 | CAR-expressing NK cell ablation of BCMA-positive malignancies |
| CN114466868A (en)* | 2020-03-20 | 2022-05-10 | 荣昌生物制药(烟台)股份有限公司 | Bispecific fusion protein and application thereof |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| WO2021209358A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein |
| WO2021218895A1 (en)* | 2020-04-29 | 2021-11-04 | 正大天晴药业集团股份有限公司 | BIFUNCTIONAL PROTEIN AGAINST PD-1 AND TGF-β |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| US20230357793A1 (en)* | 2020-06-26 | 2023-11-09 | Sorrento Therapeutics, Inc. | Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins |
| EP4178680A4 (en)* | 2020-07-10 | 2024-07-31 | Precigen, Inc. | FUSION CONSTRUCTS AND METHODS OF USE THEREOF |
| JP2023553257A (en) | 2020-11-02 | 2023-12-21 | アレス トレーディング ソシエテ アノニム | combination therapy for cancer |
| WO2022090529A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| CN116917334A (en)* | 2021-02-22 | 2023-10-20 | 浙江道尔生物科技有限公司 | Multi-domain fusion protein with anticancer activity |
| CN112979802B (en)* | 2021-04-21 | 2021-08-03 | 上海普铭生物科技有限公司 | Anti-human IL-33 monoclonal antibody and application thereof |
| CN113249330A (en)* | 2021-05-20 | 2021-08-13 | 深圳市先康达生命科学有限公司 | Immune cell and application thereof |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| US20250134998A1 (en)* | 2021-08-30 | 2025-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
| EP4396341A4 (en)* | 2021-08-31 | 2025-07-09 | Texas A & M Univ Sys | T-cell therapy platform with chimeric antigen receptor (CAR) |
| KR20240049843A (en)* | 2021-09-03 | 2024-04-17 | 풀몬진 (홍콩) 씨오., 리미티드 | Bifunctional fusion protein and uses thereof |
| US20250295694A1 (en)* | 2021-11-12 | 2025-09-25 | Georgia Tech Research Corporation | Adenosine deaminase 2 compositions and methods for using same |
| CN118339187A (en)* | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | Anti-PD-1 antibodies and their uses |
| CN114540311A (en)* | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | Immune cell and application thereof |
| CN116041539B (en)* | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | IL-2 mutant immunoconjugates |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en)* | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP0973888A1 (en) | 1997-02-06 | 2000-01-26 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
| CN1257545A (en) | 1997-04-18 | 2000-06-21 | 拜奥根有限公司 | Type II TGF-beta receptor/immunoglobulin constant region fusion proteins |
| DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CA3151350A1 (en)* | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CN102131828B (en) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | Antibody against human programmed death receptor PD-1 |
| EP3798237A1 (en)* | 2010-03-05 | 2021-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| DK2844667T3 (en) | 2012-04-30 | 2018-07-30 | Biocon Ltd | Targeted / immunomodulatory fusion proteins and methods for their preparation |
| WO2013169693A1 (en)* | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| AR094403A1 (en)* | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | ANTI-HER3 ANTIBODY COMBINATION THERAPY |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2827679T3 (en)* | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Cancer treatment with a combination of a PD-1 antagonist and dinaciclib |
| EP3705498A1 (en) | 2013-08-22 | 2020-09-09 | Acceleron Pharma Inc. | Tgf-beta receptor type ii variants and uses thereof |
| TWI681969B (en)* | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| US9676863B2 (en)* | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| CN106459924A (en)* | 2014-04-23 | 2017-02-22 | 得克萨斯州大学系统董事会 | Chimeric antigen receptors (CAR) for use in therapy and methods for making the same |
| CA3203273A1 (en)* | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CA3014067A1 (en) | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| US20180118832A1 (en)* | 2016-08-12 | 2018-05-03 | Merck Patent Gmbh | Combination therapy for cancer |
| CA3038526A1 (en) | 2016-09-27 | 2018-04-05 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| CN110198738A (en) | 2017-01-07 | 2019-09-03 | 默克专利有限公司 | The dosage regimen and dosage form that TGF-β for targeting inhibits |
| WO2018204594A1 (en) | 2017-05-04 | 2018-11-08 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| AU2018266103B2 (en)* | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| MX2019013023A (en) | 2017-05-12 | 2019-12-18 | Jiangsu Hengrui Medicine Co | FUSION PROTEIN CONTAINING TGF-ß RECEPTOR AND MEDICINAL USES THEREOF. |
| JP2021522298A (en)* | 2018-05-04 | 2021-08-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Simultaneous inhibition of PD-1 / PD-L1, TGFβ and DNA-PK for cancer treatment |
| KR20210112310A (en)* | 2018-12-06 | 2021-09-14 | 광동 티씨알큐어 바이오파마 테크놀로지 씨오., 엘티디. | TCR-T cell combination therapy targeting tumor antigens, TGF-beta and immune checkpoints |
| CN109913425B (en) | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | Recombinant influenza virus rescue method and application thereof in tumor treatment |
| JP2022537068A (en)* | 2019-06-23 | 2022-08-23 | グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド | Anti-ALPP CAR-T cell therapy |
| Publication number | Publication date |
|---|---|
| US20200048351A1 (en) | 2020-02-13 |
| JP2025063123A (en) | 2025-04-15 |
| CN112672753B (en) | 2025-07-08 |
| US11535669B2 (en) | 2022-12-27 |
| ZA202300423B (en) | 2025-04-30 |
| KR20210042909A (en) | 2021-04-20 |
| EP3820496A4 (en) | 2022-04-20 |
| EP3820496A2 (en) | 2021-05-19 |
| CN112672753A (en) | 2021-04-16 |
| IL279965A (en) | 2021-03-01 |
| WO2020014285A3 (en) | 2020-03-12 |
| CA3105750A1 (en) | 2020-01-16 |
| JP7617839B2 (en) | 2025-01-20 |
| US20240141045A1 (en) | 2024-05-02 |
| AU2019301070B2 (en) | 2025-09-11 |
| ZA202100390B (en) | 2023-10-25 |
| JP2021531754A (en) | 2021-11-25 |
| WO2020014285A2 (en) | 2020-01-16 |
| AU2019301070A1 (en) | 2021-01-21 |
| Publication | Publication Date | Title |
|---|---|---|
| IL279965A (en) | Fusion constructs and methods of using thereof | |
| IL288373A (en) | Flt3l-fc fusion proteins and methods of use | |
| IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
| IL265605A (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SI3655006T1 (en) | Ultra-long acting insulin-fc fusion proteins and methods of use | |
| HUE062436T2 (en) | Anti-trem2 antibodies and methods of use thereof | |
| RS64576B1 (en) | Anti-tigit antibodies and methods of use thereof | |
| SG10202112024PA (en) | Chimeric proteins and methods of immunotherapy | |
| IL267861A (en) | A pd1-41bbl fusion protein and methods of use thereof | |
| IL275070A (en) | Fcrn antibodies and methods of use thereof | |
| EP3261650A4 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| IL267862A (en) | A sirpalpha-41bbl fusion protein and methods of use thereof | |
| IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
| SG11202102644XA (en) | Methods and uses of variant cd80 fusion proteins and related constructs | |
| EP3706786A4 (en) | Bispecific fusion polypeptides and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| IL276187A (en) | Mica/b antibodies and methods of use | |
| IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
| ZA202002144B (en) | Antibodies and methods of use | |
| IL268234A (en) | Factor ix fusion proteins and methods of making and using same | |
| IL286799A (en) | Fusion constructs and uses thereof | |
| HK40042278A (en) | Fusion constructs and methods of using thereof | |
| HK40092667A (en) | Chimeric receptors and methods of use thereof | |
| HK40037115A (en) | Modified chimeric antigen receptors and methods of use | |
| HK40037614A (en) | Bispecific fusion polypeptides and methods of use thereof |